Aethlon Medical (NASDAQ:AEMD) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Aethlon Medical (NASDAQ:AEMD) announced its earnings results on Thursday. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10), FiscalAI reports.

Here are the key takeaways from Aethlon Medical’s conference call:

• Positive Sentiment: Aethlon has entered the final cohort of its Australian oncology trial, with only two additional participants needed if no further safety events occur; the company targets completion of treatments and follow-up by year-end 2026 or early 2027.
• Positive Sentiment: Preliminary, unstatistical analyses from cohort 2 showed more consistent and longer-lasting reductions in extracellular vesicles and cancer-related microRNAs, along with favorable directional changes in lymphocyte subsets and immunotherapy-related laboratory ratios than in cohort 1.
• Neutral Sentiment: Preclinical research found that the Hemopurifier’s resin can bind extracellular vesicles in long COVID samples and reduce certain inflammation- and immune-dysregulation-associated microRNAs; the company is evaluating potential clinical paths and additional work in lupus and heart disease related to chronic kidney disease.
• Positive Sentiment: Cash and cash equivalents totaled approximately $4.9 million at quarter-end, and a subsequent public offering raised about $4 million in gross proceeds; management believes current resources can fund operations for at least 12 months, while quarterly operating expenses declined 11.9% year over year to approximately $1.6 million.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $2.83 on Friday. The company has a market cap of $1.84 million, a PE ratio of -0.04 and a beta of 1.41. Aethlon Medical has a 12 month low of $2.63 and a 12 month high of $137.00. The company has a fifty day moving average price of $4.83 and a two-hundred day moving average price of $8.78.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AEMD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aethlon Medical has a consensus rating of “Sell”.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. Institutional investors and hedge funds own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.